United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - podofilox (unii: l36h50f353) (podofilox - unii:l36h50f353) - podofilox 5 mg in 1 ml

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - podofilox (unii: l36h50f353) (podofilox - unii:l36h50f353) - podofilox 5 mg in 1 g

United States - English - NLM (National Library of Medicine)

padagis us llc - podofilox (unii: l36h50f353) (podofilox - unii:l36h50f353) - podofilox 5 mg in 1 ml - podofilox topical solution 0.5% is indicated for the topical treatment of external genital warts (condyloma acuminatum). this product is not indicated in the treatment of perianal or mucous membrane warts (see precautions ). although genital warts have a characteristic appearance, histopathologic confirmation should be obtained if there is any doubt of the diagnosis. differentiating warts from squamous cell carcinoma (so-called "bowenoid papulosis") is of particular concern. squamous cell carcinoma may also be associated with human papillomavirus but should not be treated with podofilox topical solution 0.5%. podofilox topical solution 0.5% is contraindicated for patients who develop hypersensitivity or intolerance to any component of the formulation.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - podofilox (unii: l36h50f353) (podofilox - unii:l36h50f353) - podofilox 5 mg in 1 ml - podofilox 0.5% solution is indicated for the topical treatment of external genital warts (condyloma acuminatum). this product is not indicated in the treatment of perianal or mucous membrane warts (see precautions). although genital warts have a characteristic appearance, histopathologic confirmation should be obtained if there is any doubt of the diagnosis. differentiating warts from squamous cell carcinoma (so-called “bowenoid papulosis”) is of particular concern. squamous cell carcinoma may also be associated with human papillomavirus but should not be treated with podofilox 0.5% solution. podofilox 0.5% solution is contraindicated for patients who develop hypersensitivity or intolerance to any component of the formulation.

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - podofilox (unii: l36h50f353) (podofilox - unii:l36h50f353) - podofilox 5 mg in 1 ml - podofilox 0.5% solution is indicated for the topical treatment of external genital warts (condyloma acuminatum). this product is not indicated in the treatment of perianal or mucous membrane warts (see precautions). although genital warts have a characteristic appearance, histopathologic confirmation should be obtained if there is any doubt of the diagnosis. differentiating warts from squamous cell carcinoma (so-called “bowenoid papulosis”) is of particular concern. squamous cell carcinoma may also be associated with human papillomavirus but should not be treated with podofilox 0.5% solution. podofilox 0.5% solution is contraindicated for patients who develop hypersensitivity or intolerance to any component of the formulation.

United States - English - NLM (National Library of Medicine)

allergan, inc. - podofilox (unii: l36h50f353) (podofilox - unii:l36h50f353) - podofilox 5 mg in 1 g - condylox gel 0.5% is indicated for the topical treatment of anogenital warts (external genital warts and perianal warts). this product is not indicated in the treatment of mucous membrane warts (see precautions ). although anogenital warts have a characteristic appearance, histopathologic confirmation should be obtained if there is any doubt of the diagnosis. differentiating warts from squamous cell carcinoma and "bowenoid papulosis" is of particular concern. squamous cell carcinoma may also be associated with human papillomavirus which should not be treated with condylox gel 0.5%. condylox gel 0.5% is contraindicated for patients who develop hypersensitivity or intolerance to any components of the formulation.

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - podofilox (unii: l36h50f353) (podofilox - unii:l36h50f353) - podofilox 0.5% solution is indicated for the topical treatment of external genital warts (condyloma acuminatum). this product is not indicated in the treatment of perianal or mucous membrane warts (see precautions). although genital warts have a characteristic appearance, histopathologic confirmation should be obtained if there is any doubt of the diagnosis. differentiating warts from squamous cell carcinoma (so-called “bowenoid papulosis”) is of particular concern. squamous cell carcinoma may also be associated with human papillomavirus but should not be treated with podofilox 0.5% solution. podofilox 0.5% solution is contraindicated for patients who develop hypersensitivity or intolerance to any component of the formulation.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - podophyllotoxin -

Israel - English - Ministry of Health

takeda israel ltd - podophyllotoxin - solution - podophyllotoxin 5 mg/ml - podophyllotoxin - podophyllotoxin - treatment of external genital warts (condyloma acuminatum).

Malta - English - Medicines Authority

glaxo smithkline uk limited 980 great west road, brentford, middlesex, tw8 9gs, united kingdom - podophyllotoxin - cream - podophyllotoxin 0.15 % (w/w) - antibiotics and chemotherapeutics for dermatological use